Concourse Financial Group Securities, Inc. Cardiff Oncology, Inc. Transaction History

Concourse Financial Group Securities, Inc.

  • $1.64 Billion
  • Q3 2024
Number of Shares
0
Previous 0 NaN%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024
BUY
$2.05 - $2.77 $0 - $0
0 New
0 $0
Q2 2024

Jul 23, 2024
BUY
$2.22 - $5.89 $0 - $0
0 New
0 $0
Q1 2024

Apr 30, 2024
BUY
$1.46 - $5.91 $0 - $0
0 New
0 $0
Q4 2023

Feb 07, 2024
BUY
$0.96 - $1.55 $0 - $0
0 New
0 $0
Q3 2023

Oct 30, 2023
BUY
$1.38 - $2.18 $0 - $0
0 New
0 $0
Q3 2023

Oct 25, 2023
BUY
$1.38 - $2.18 $0 - $0
0 New
0 $0
Q2 2023

Aug 10, 2023
BUY
$1.37 - $1.95 $0 - $0
0 New
0 $0
Q1 2023

May 15, 2023
BUY
$1.45 - $2.09 $0 - $0
0 New
0 $0
Q4 2022

Jan 30, 2023
BUY
$1.22 - $1.66 $0 - $0
0 New
0 $0
Q3 2022

Nov 15, 2022
BUY
$1.54 - $3.21 $0 - $0
0 New
0 $0
Q2 2022

Aug 09, 2022
BUY
$1.17 - $2.61 $0 - $0
0 New
0 $0
Q1 2022

May 09, 2022
BUY
$2.11 - $7.25 $0 - $0
0 New
0 $0
Q4 2021

Feb 07, 2022
BUY
$5.18 - $7.24 $0 - $0
0 New
0 $0
Q3 2021

Nov 09, 2021
BUY
$5.01 - $7.58 $0 - $0
0 New
0 $0
Q2 2021

Aug 13, 2021
BUY
$6.65 - $10.04 $0 - $0
0 New
0 $0
Q1 2021

May 13, 2021
BUY
$9.1 - $19.57 $0 - $0
0 New
0 $0
Q4 2020

Feb 02, 2021
BUY
$12.02 - $24.71 $0 - $0
0 New
0 $0
Q3 2020

Nov 13, 2020
BUY
$4.25 - $14.19 $0 - $0
0 New
0 $0
Q2 2020

Aug 13, 2020
BUY
$0.78 - $5.1 $0 - $0
0 New
0 $0

Others Institutions Holding CRDF

# of Institutions
90
Shares Held
12.3M
Call Options Held
813K
Put Options Held
91.1K
View Full List

About Cardiff Oncology, Inc.

CRDF Quotes by TradingView
  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $110M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email